Clinical trials: Metabolic Evaluation
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2…
- Trial name
- NCT01492166
- Testing
- biphasic human insulin 30
- Where
- Indonesia
- Volunteers
- 1,935 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 686 sites in United States, Argentina and 33 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion.
- Trial name
- DEFEND-1 (NCT00678886)
- Testing
- otelixizumab infusion plus physician determined standard of care
- Where
- 109 sites in United States, Canada and 7 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Obesity
Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study
The objectives of this clinical research project are to demonstrate the safety and feasibility of CAVU Medical, Inc.'s Attune Device.
- Trial name
- NCT01422941
- Testing
- CAVU Attune Device
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Cavu Medical, Inc.
Healthy Participant Study
RE104 Radiolabeled Mass Balance (hAME) Study
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers.
- Trial name
- NCT07146191
- Testing
- 2-[14C]-RE104 for Injection
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Reunion Neuroscience Inc
Diabetes, Diabetes Mellitus, Type 2
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes.
- Trial name
- LEAD-3 (NCT00294723)
- Testing
- liraglutide, glimepiride
- Where
- 117 sites in United States, Mexico and 1 more
- Volunteers
- 746 people
- Sponsor
- Novo Nordisk A/S
Sphingomyelin Lipidosis
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
Primary Objective: To evaluate the safety and tolerability of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks.
- Trial name
- ASCEND-Peds (NCT02292654)
- Testing
- Olipudase alfa
- Where
- 6 sites in United States, Brazil and 4 more
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Gout, Hyperuricemia
Mass Balance Study of [14C]LC350189 in Healthy Volunteers
This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of [14C] radiolabeled LC350189 after oral administration.
- Trial name
- NCT04070846
- Testing
- [14C] LC350189
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- LG Chem
Lactose Intolerance
Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance
The goal of this clinical trial is to test whether a new combination of lactase and bacterial strain (L. Salivarius DSM 34078) can provide longer lasting beneficial effects on lactose digestion and gastrointestinal symptoms…
- Trial name
- NCT06107088
- Testing
- Active 1, Active 2, Active 3
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Novozymes A/S
Hypoglycemia
Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207
The trial is a single-centre, randomized, double-blind, phase 1b trial of multiple ascending doses of ZP4207 administered s.c. to healthy volunteers (HV) to evaluate the safety, tolerability, pharmakocinetic (PK) and…
- Trial name
- NCT02390141
- Testing
- ZP4207
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Diabetes Mellitus, Type 2
A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM
The purpose of the proposed work is to assess the effects of a dietary supplement, containing chromium (600 mcg per day) provided by chromium picolinate and biotin (2 mg per day) on glycemic control in type 2 diabetes.
- Trial name
- NCT00308451
- Testing
- Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Nutrition 21, Inc.
Overweight, Healthy
A Study of LY3541105 in Healthy and Overweight Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it…
- Trial name
- NCT05380323
- Testing
- LY3541105
- Where
- 2 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT07193459
- Testing
- HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Hyperphosphatemia
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
The aim of the study is: To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses； To evaluate the…
- Trial name
- NCT04440696
- Testing
- Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Grand Life Science (Liaoning) Co., Ltd.
Type 2 Diabetes
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting…
- Trial name
- NCT01195662
- Testing
- Dapagliflozin
- Where
- 298 sites in United States, Australia and 14 more
- Volunteers
- 2,245 people
- Sponsor
- AstraZeneca
Dyslipidemias
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A
- Trial name
- NCT04874129
- Testing
- YYC506-T and YYC506-A (phase 1), YYC506 (phase 1), YYC506-T and YYC506-A (phase 2)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Severe Hypertriglyceridemia
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus…
- Trial name
- NCT07680829
- Testing
- DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule
- Where
- 2 sites in China
- Volunteers
- 378 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Hypercholesterolemia
A Study on the Effects of Soy Protein on Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia
The objectives of the trial are to determine whether a non-commercial soy protein product, consumed as part of a low-saturated fat diet, reduces low-density lipoprotein cholesterol (LDL-C) concentrations in men and women with…
- Trial name
- PRV-08009 (NCT00945737)
- Testing
- Soy protein; 25 grams/day, Control protein
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Solae, LLC
Type 2 Diabetes
Assessment of Probiotics on Inflammation and Metabolism in Type 2 Diabetes.
This clinical study aims to explore the effects of probiotics on inflammatory and metabolic indicators in patients with type 2 diabetes.
- Trial name
- NCT06440486
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Wecare Probiotics Co., Ltd.
Type 2 Diabetes Mellitus
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients
The purpose of this study is to obtain information on PK/PD, efficacy and safety of SHR3824 over 12 weeks in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT02366351
- Testing
- SHR3824
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.